9-Jun-2026
Omeros Corporation Reports First Quarter 2026 Financial Results
Business Wire (Wed, 13-May 4:02 PM ET)
Omeros to Announce Q1 2026 Financial Results Amid Key Product Developments and Novo Nordisk Deal
Market Chameleon (Tue, 12-May 5:39 AM ET)
Omeros Corporation to Announce First Quarter Financial Results on May 13, 2026
Business Wire (Mon, 11-May 4:02 PM ET)
Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical Officer
Globe Newswire (Mon, 20-Apr 7:00 AM ET)
Market Chameleon (Thu, 16-Apr 5:24 AM ET)
CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA (narsoplimab-wuug)
Business Wire (Thu, 16-Apr 8:45 AM ET)
Market Chameleon (Wed, 1-Apr 7:08 AM ET)
Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results
Business Wire (Tue, 31-Mar 4:02 PM ET)
Omeros Corporation to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 31, 2026
Business Wire (Thu, 26-Mar 8:45 AM ET)
Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment
Business Wire (Sat, 21-Mar 3:23 AM ET)
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.
Omeros trades on the NASDAQ stock market under the symbol OMER.
As of June 9, 2026, OMER stock price climbed to $9.97 with 1,464,642 million shares trading.
OMER has a beta of 2.71, meaning it tends to be more sensitive to market movements. OMER has a correlation of 0.10 to the broad based SPY ETF.
OMER has a market cap of $721.58 million. This is considered a Small Cap stock.
Last quarter Omeros reported $10 million in Revenue and -$.24 earnings per share. This fell short of revenue expectation by $-157,000 and exceeded earnings estimates by $.06.
In the last 3 years, OMER traded as high as $17.65 and as low as $.92.
The top ETF exchange traded funds that OMER belongs to (by Net Assets): VTI, IWM, VXF, PBE, XPH.
OMER has outperformed the market in the last year with a return of +164.5%, while the SPY ETF gained +24.3%. However, in the most recent history, OMER shares have underperformed the stock market with its stock returning -13.6% in the last 3 month period and -13.0% for the last 2 week period, while SPY has returned +9.9% and -1.2%, respectively.
OMER support price is $9.48 and resistance is $10.22 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OMER shares will trade within this expected range on the day.
